Glycostat (Bitter Melon Extract)

Glycostat is a standardized bitter melon (Momordica charantia) extract concentrated in charantin, polypeptide-p, and vicine, bioactive compounds that activate AMPK and mimic insulin signaling to support healthy glucose metabolism. Unlike conventional bitter melon preparations, Glycostat is derived from a specific varietal selected for superior potency and has been clinically compared against Chinese and Indian bitter melon strains in controlled trials.

Origin & History

Glycostat is a patented, proprietary extract (U.S. Patent #10,006,079) derived from a wild genotype of bitter melon (Momordica charantia), a tropical plant traditionally used in Asia, Africa, and the West Indies. It is produced via a 15:1 concentration process with stabilization to retain activity from fresh wild bitter melon, distinguishing it as superior to standard varietals in comparative research.

Historical & Cultural Context

Bitter melon has been used for centuries in Ayurveda, Traditional Chinese Medicine, and folk systems of Asia, Africa, and the West Indies to support cardiovascular and metabolic functions, including blood sugar regulation. Glycostat leverages wild genotypes historically tied to these practices, though its proprietary standardized form is modern.

Health Benefits

• Supports healthy blood sugar levels without raising insulin, as shown in a 60-day comparative trial where it outperformed Chinese and Indian bitter melon varietals (evidence quality: moderate)
• Promotes cardiovascular health through ACE inhibition and blood pressure support within normal ranges (evidence quality: preliminary from comparative study)
• Enhances glucose tolerance and insulin sensitivity based on GTT parameter improvements (evidence quality: moderate from single comparative trial)
• Provides anti-inflammatory effects via nitric oxide suppression with IC50 15-18 µM in cell models (evidence quality: preliminary, in-vitro only)
• Delivers antioxidant support through flavonoids, phenolic acids, and vitamin C content (evidence quality: traditional/theoretical)

How It Works

Glycostat's primary bioactives—charantin and polypeptide-p—activate AMP-activated protein kinase (AMPK) in skeletal muscle and hepatic tissue, enhancing GLUT4 translocation to the cell membrane and increasing peripheral glucose uptake independent of insulin secretion. Vicine and charantin also inhibit glucose-6-phosphatase and fructose-1,6-bisphosphatase, reducing hepatic glucose output. Additionally, peptide fractions within the extract act as angiotensin-converting enzyme (ACE) inhibitors, attenuating vasoconstriction and supporting blood pressure within normal physiological ranges.

Scientific Research

Glycostat has been evaluated in one published 60-day comparative trial where it outperformed Chinese and Indian bitter melon varietals in glucose tolerance test parameters and blood pressure support, though specific study design details and PMIDs are not provided. While broader bitter melon research includes RCTs showing improved glucose metabolism (DiLonardo M.J., 2024, no PMID) and lipid effects (Kinoshita, 2018, no PMID), no Glycostat-specific human RCTs with PMIDs were identified.

Clinical Summary

A 60-day comparative trial evaluated Glycostat against Chinese and Indian bitter melon varietals and found Glycostat to be superior in supporting healthy fasting blood glucose levels, though exact sample size and delta values from this proprietary study have not been fully published in peer-reviewed literature, limiting independent verification. Broader Momordica charantia research includes randomized controlled trials with sample sizes ranging from 40 to 200 participants, generally demonstrating modest reductions in fasting glucose and HbA1c over 4–12 weeks. A meta-analysis of bitter melon RCTs found statistically significant but clinically modest improvements in glycemic markers, with effect sizes varying substantially by extract type and standardization. Overall, evidence quality for Glycostat specifically is rated moderate, with stronger support coming from the compound class level than from Glycostat-specific published human trials.

Nutritional Profile

Glycostat is a standardized bitter melon (Momordica charantia) extract, not a whole food ingredient, so macronutrient content is negligible at typical supplemental doses (250–500 mg). Key bioactive compounds include: charantin (a steroidal glycoside mixture of sitosteryl glucoside and stigmasteryl glucoside, typically standardized to 1–5% in extracts), polypeptide-p (plant insulin analog, also called p-insulin, ~17 kDa peptide), vicine and momordicine (pyrimidine nucleoside and alkaloid compounds contributing to hypoglycemic activity), and momordicosides (cucurbitane-type triterpenoid glycosides). Glycostat specifically references optimization across bitter melon varietals (Chinese and Indian Momordica charantia), suggesting a concentrated or blended extract standardized for consistent charantin and polypeptide-p levels. Micronutrient contribution at extract doses is minimal, though whole bitter melon is a source of vitamin C (~84 mg/100g fresh weight), folate (~72 mcg/100g), zinc, iron, and potassium — these are largely concentrated out in extract form. Fiber content is negligible in extract form. Bioavailability: charantin and triterpenoids are lipophilic and benefit from co-ingestion with dietary fat; absorption is moderate and subject to first-pass metabolism; polypeptide-p has limited oral bioavailability due to proteolytic degradation but may exert localized intestinal effects on glucose transporters (GLUT4 upregulation noted in vitro).

Preparation & Dosage

Clinically studied dosage for Glycostat is 1500 mg daily (2 tablets of 750 mg each, 15:1 extract), as used in the 60-day comparative trial. Products are available in tablet/capsule form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Chromium picolinate, Alpha-lipoic acid, Cinnamon extract, Gymnema sylvestre, Berberine

Safety & Interactions

Glycostat and bitter melon extracts are generally well tolerated at typical doses, but gastrointestinal side effects including nausea, abdominal cramping, and diarrhea have been reported, particularly at higher doses or on an empty stomach. Significant drug interactions exist with antidiabetic medications including metformin, sulfonylureas, and insulin, as additive blood glucose-lowering effects may increase hypoglycemia risk, warranting close monitoring and physician supervision. Bitter melon is contraindicated in pregnancy due to uterotonic properties of momorcharin and vicine, which may stimulate uterine contractions. Individuals with G6PD deficiency should avoid bitter melon preparations containing vicine and convicine, which can trigger hemolytic anemia.